GSK Receives FDA Approval for a New Self-Injectable Formulation of Benlysta (belimumab) for Systemic Lupus Erythematosus

London, UK 21 July 2017 -- GSK announced today that the US Food and Drug Administration (FDA) has approved a new subcutaneous formulation of Benlysta (belimumab) for the treatment of adult patients with active, autoantibody ‑positive SLE who are...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news